Download PDF

1. Company Snapshot

1.a. Company Description

Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally.The company operates through three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail.The Commercial & Clinical division offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers; and distribution and support services to medical device manufacturers.


The Product Access division provides on demand services, which provides access to pharmaco-medical products and treatments by developing valuable relationships and interactions between manufacturers and other healthcare stakeholders; and exclusive access services that offers bespoke distribution partnerships to pharmaceutical partners for key brands.The Supply Chain & Retail division engages in pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons; and operates a network of pharmacies under the Life, Allcare, and Hickey's brands.It also offers pharmacy support, pharmaceutical supply chain, specialist nursing and infusion, medical device distribution, healthcare technology, data intelligence and consultancy services, pharmaceutical advisory, medical affairs, and online pharmacy and product fostering services, as well as data solutions for pharma industry.


Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.

Show Full description

1.b. Last Insights on UPR

Uniphar plc's recent performance was driven by a favorable market environment, with easing inflation and strong bank earnings propelling stocks higher. The company's robust financial health, as highlighted in recent market analysis, positions it as an attractive investment opportunity. Additionally, Uniphar's solid financial foundations and potential for growth make it a promising pick among European penny stocks. Furthermore, the company's recent inclusion in market watchlists, such as the list of European penny stocks with promising prospects, underscores its potential for value and opportunity.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

European Penny Stocks: Tractial And 2 More Under-The-Radar Opportunities

Aug -28

Source:

Card image cap

European Penny Stocks To Watch With Market Caps Over €100M

Jul -30

Source:

Card image cap

3 European Penny Stocks With Market Caps Under €1B To Consider

Jul -01

Source:

Card image cap

Cairo Communication Among 3 European Penny Stocks To Watch

May -26

Source:

Card image cap

Cairo Communication Leads The Charge In European Penny Stocks

Apr -25

Source:

Card image cap

March 2025 European Penny Stocks With Promising Prospects

Mar -27

Source:

Card image cap

Uniphar And Two Other Promising Penny Stocks To Watch

Feb -24

Source:

Card image cap

Uncovering Opportunities: 3 Penny Stocks With Market Caps Under US$500M

Jan -22

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (1.14%)

6. Segments

Uniphar Supply Chain & Retail

Expected Growth: 1.2%

Uniphar Supply Chain & Retail's 1.2% growth is driven by increasing demand for healthcare products, strategic partnerships with pharmacies, and investments in digital platforms enhancing customer experience. Additionally, the segment benefits from Uniphar's diversified customer base, efficient logistics, and cost-saving initiatives.

Uniphar Pharma

Expected Growth: 0.8%

Uniphar Pharma's 0.8% growth is driven by increasing demand for specialty medicines, strategic partnerships, and expansion into new markets. Additionally, the company's focus on digital transformation, cost savings initiatives, and investment in research and development are contributing to its growth momentum.

Uniphar Medtech

Expected Growth: 1.5%

Uniphar Medtech's 1.5% growth is driven by increasing demand for medical devices, expansion into new markets, and strategic partnerships. Additionally, investments in R&D and digitalization efforts are enhancing product offerings and improving operational efficiency. Furthermore, the growing need for healthcare services and the aging population are contributing to the segment's growth.

7. Detailed Products

Pharmaceutical Distribution

Uniphar plc provides pharmaceutical distribution services to pharmacies, hospitals, and other healthcare providers, offering a wide range of products from leading manufacturers.

Retail Pharmacy Services

Uniphar plc operates a chain of retail pharmacies, offering a range of healthcare services, including dispensing, health checks, and medication management.

Medical Devices and Consumables

Uniphar plc supplies medical devices and consumables to healthcare providers, including hospitals, clinics, and medical practices.

Pharmaceutical Wholesale

Uniphar plc provides pharmaceutical wholesale services to pharmacies, hospitals, and other healthcare providers, offering a wide range of products from leading manufacturers.

Healthcare Services

Uniphar plc offers a range of healthcare services, including health checks, vaccination programs, and medication management services.

8. Uniphar plc's Porter Forces

Forces Ranking

Threat Of Substitutes

Uniphar plc operates in the pharmaceutical industry, where there are limited substitutes for its products. However, there is a growing trend towards generic and biosimilar drugs, which could pose a threat to the company's revenue.

Bargaining Power Of Customers

Uniphar plc's customers are primarily pharmacies and hospitals, which have limited bargaining power due to the company's strong market position and diversified product portfolio.

Bargaining Power Of Suppliers

Uniphar plc relies on a network of suppliers for its products, but it has a diversified supplier base, which reduces its dependence on any one supplier. However, the company is still vulnerable to supply chain disruptions.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs, which makes it difficult for new entrants to enter the market.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. Uniphar plc faces intense competition from other pharmaceutical companies, which could impact its market share and revenue.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 53.44%
Debt Cost 6.77%
Equity Weight 46.56%
Equity Cost 7.71%
WACC 7.21%
Leverage 114.78%

11. Quality Control: Uniphar plc passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotest

A-Score: 5.6/10

Value: 7.6

Growth: 7.4

Quality: 2.4

Yield: 0.0

Momentum: 6.0

Volatility: 10.0

1-Year Total Return ->

View Full Report
Stock-Card
Uniphar

A-Score: 5.2/10

Value: 4.3

Growth: 5.7

Quality: 3.4

Yield: 1.2

Momentum: 9.5

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
RaySearch Laboratories

A-Score: 4.9/10

Value: 0.5

Growth: 8.4

Quality: 7.6

Yield: 1.2

Momentum: 9.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Arjo

A-Score: 4.5/10

Value: 7.3

Growth: 3.8

Quality: 5.6

Yield: 3.8

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Boiron

A-Score: 4.5/10

Value: 5.7

Growth: 2.1

Quality: 6.2

Yield: 8.8

Momentum: 1.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Selvita

A-Score: 2.3/10

Value: 3.5

Growth: 4.9

Quality: 3.7

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.21$

Current Price

3.21$

Potential

-0.00%

Expected Cash-Flows